Liver and Pancreas Tumors
Questions discussed in this category
The patient declined palliative measures only and is motivated to receive treatment
Post-operative surgical course was complicated by anastomotic leak, septic shock, candidemia, wound infections, PE & DVT. Now recovering well.
Would you treat as cholangiocarcinoma with a gemcitabine/platinum regimen or would you use a more HCC regimen like atezo/bev or durva/trem?
The Mayo Clinic protocol recommends initial fields -1.5 Gy BID initially to 45 Gy followed by a Brachytherapy boost. If HDR /LDR is not available, wha...
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?
...
When using hypofractionated RT (i.e., 67.5 Gy in 15 fractions), can chemotherapy be delivered concurrently?
Options for systemic therapy in NCC...
Would portal hypertensive gastropathy or colopathy sway you away from using it?
And if delayed, should chemotherapy be started?
And is there any role in utilizing FGFR2 inhibitors in first line setting?
The PROOF trial utilizing Infigratinib in first line was stopped after the...
Do you continue atezo alone if responding or switch to an alternative therapy such as dual IO or TKI? What about if the patient were experiencing subt...
From NCCN (Rectal MS-33): SBRT is a reasonable option for patients who cannot be resected or ablated.
What is the role of SBRT versus microwave ablat...
Plan to give adjuvant chemotherapy.
Should Y90 be offered before or after TACE (based on the Northwestern phase 2 study) or sorafenib (based on the SARAH trial)?
Or offer resection followed by adjuvant therapy?
Would you offer single agent immunotherapy or chemo-immunotherapy with gem/cis durva/pembro?
Is liquid biopsy helpful? Would you treat if this shows somatic mutation?
Will the results of the recently published randomized comparison of proton beam therapy (PBT) vs. transarterial chemoembolization (TACE) change the wa...
I can't convince the surgeons to refer their patients for adjuvant RT because the prospective data is messy and doesn’t seem to indicate a benef...
Please specify how your institution is allocating resources now or will be soon.
Would you use immunotherapy based on the TOPAZ trial?
If borderline resectable, can the TOPAZ regimen be considered for downstaging effects?
How do you sequence systemic treatment options for in patients with Child's Pugh B (or greater) in context of IMbrave150 and HIMALAYA?
When do you in...
Is data sufficient to adopt this as the new standard of care?
Can you comment on the reported regional and race-based variations in outcomes? ...
Would you consider switching to a different regimen?
The patient already received PLADO+sorafenib, Y90, and Atezolizumab/Bevacizumab complicated by recurrent episodes of bleeding from esophageal varices....
If multi-agent systemic therapy, i.e. FOLFIRINOX, is also planned, is there a preferred sequence of therapies?
Would the etiology of HCC affect your decision, e.g. non-viral hepatitis since less benefit was shown for this group in IMbrave150?
The patient was started on a beta blocker, as this is standard in the area.
Would you consider using infigratinib after progression on pemigatinib?
Would you offer liver transplant in the setting of metastatic disease?
What therapy would you offer if the patient had a baseline grade 2 neuropathy?
Colloid is a rare histologic subtype and considered to have more favorable outcomes compared with usual ductal adenocarcinoma, but no dedicated prospe...
Has the recent approval of atezolizumab/bevacizumab impacted your decision making?
Would you recommend radiation, systemic therapy alone, or chemoRT? What about if this recurrence occurred during or shortly after completion of adjuva...
Would you offer low dose or standard dose aspirin instead?
If so, do you avoid pegfilgrastim given that <12 days will lapse between its administration and the next cycle?
Would you try atezolizumab/bevacizumab or switch to a TKI?
When would you consider gemcitabine/abraxane as an alternative treatment?
Would you reduce dose, e.g. from 30 Gy in 10 fractions to 20 Gy in 5 fractions, or hyperfractionate, e.g. 1.5 Gy bid to 20-30 Gy?
Specifically, would you consider incorporating immunotherapy in this setting?
For example in a patient with a history of PE?
i.e. EGD surveillance for varices?
What parameters do you use to decide to treat beyond progression? Is there any efficacy data from this specific study subgroup in IMbrave150?
ex. VEGFR2 expression, inflammatory signature, PDL1, etc.
Do you continue atezolizumab alone? Would you avoid anticoagulation?
In light of the SIRveNIB trial results and now IMbrave150, what is the role of intra-arterial therapy now?
Do you screen even asymptomatic patients?
In a patient with a large primary and a negative PET/CT for nodal disease, would you push for EUS for radiation planning? Or would this be an unnecess...
Patient had a solitary lung metastasis
For example, a FANC mutation
Would age influence your decision?
Is there evidence for radiation therapy in this setting?
What are there most evidence-based options?
Do you recommend TACE, RFA, radioembolization, systemic therapy or SBRT? What if the size is >5 cm?
Are you placing more weight on patient risk factors such as age >65 or co-morbidities?
Patients oftentimes have cardiac co-morbidities with requirement for anti-coagulation making TKIs, including Bevacizumab, difficult to dose. Would the...
Would you consider single agent IO such as Nivolumab, given data are not strong (Checkmate 459)?
Upfront surgery vs neoadjuvant therapy? And if neoadjuvant therapy, which regimen?
Patient has a good PS.
Quite often we encounter cholestatic hyperbilirubinemia, wherein GI and IR do not believe ERCP with stents or PTC will alleviate jaundice. If the pati...
Does this also apply to somatic mutations?
With extensive use of NGS testing, it is commonplace to identify mutations that have no validated therapeutic intervention, but strong biologic signal...
In your experience, what approach has been successful to bridge to surgery?
ex. age, surgical risk, and/or performance status
Up to six cycles of treatment were given in the ABC02 trial. Do you offer other treatments if you don't continue gem/cis beyond 24 weeks?
If so, for what platelet count threshold and do you have a preference as to which agent?
Given the variable and sometimes indolent disease course of these patients, as well as the absence of a clear overall survival benefit in the PROMID&n...
Is there a "best" way to approach treatment of the viral infection i.e concurrently with therapy, prior to therapy, delayed or post therapy? Does this...
If you do employ this strategy, are there a number of liver lesions (eg <4) or duration of response that guide your decision making?
Would you alter your SBRT dose? How long would you hold the VEGF inhibitor before and after? Does the primary matter (e.g. NSCLC vs. colorectal)?
A pilot study has shown activity of this combination in a small patient group.
A number of phase 2 trials support various combinations (e.g. gem/ox, cape/cis, cape/ox, 5-FU based) -- how do you decide either between these regimen...
Would you consider adding trastuzumab to cis/gem in the first line? If not, would you consider adding Her2 directed therapy to FOLFIRI or FOLFOX in th...
Do you continue with FOLFIRI for a period and then switch to olaparib (and if so, when do you make that switch) or do you switch directly after FOLFIR...
How would you approach this situation in the absence of BRCA mutation data?
I have seen anywhere from 4-6 months utilized. Is there any data to guide your strategy?
Patient characteristics would unarguably be a deciding factor, but outside of these how would you approach the situation?
Do you have any preferred dose fractionation schedules? What kind of margins do you use?
Arterial events have clear instructions to permanently discontinue on the FDA label. Especially in HCC without many other treatment options, giv...
Is there a role for SBRT with or without the addition of systemic therapy?
The patient had minimal to no response to neoadjuvant therapy.
What features would make you more likely to recommend radiation therapy with chemotherapy?
If so, which agent(s) do you prefer?
The GTX (gemcitabine, docetaxel, capecitabine) regimen is listed as a category 2B recommendation in the NCCN guidelines- when would this be ...
Stenting is not possible/not able to bring down the bilirubin level.
Regorafenib has been approved for patients with advanced HCC post-sorafenib, but the benefits are slight and toxicity substantial. Nivolumab has...
Have you ever seen toxicity related to diaphragm dose with conventional fractionation?
How would the new data presented at ASCO GI 2021 from from Alliance A021501 influence your answer?
When planning SBRT cases for primary liver cancers, it is very difficult to see the tumor on the non-contrast 4D scan. How do you use information from...
What are the targets (tumor bed, positive margin, nodes etc.)?
For cases with positive margins, do you boost to 54 Gy? If so, do you boost the entire tumor bed or only the area of the positive margin?
I recently had a patient with unresectable disease ask for a PET before starting RT but I’m not sure there is a benefit.
What techniques work best?
213762137921071211072091215342196001580017107187051924518917189335721196918404173731827533611788617840176961660517461169812951656116380100171616215900150081477314643146161195512005643112347134011246011539128746161119461192511332108031079793479872104051045110177636272794566423962695549257932592609208925892338823384090918460872572177147826882628612826182608259825881838160815574117815795878827745771257617619754373717413739534566769663445057014670069456802687969026775515966246368643863676301630761401138606860565869600159534242384259245886579655125713576357055501568253995618476550804415500448233693470546944592759760258726492563210420001601189971418391377757756931623818294296
Papers discussed in this category
Cancer, 2007-11-15
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-07-20
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-07-20
Cancer, 1987 Jun 15
Ann Surg, 2007 Nov
Cancer, 2015-04-01
JAMA, 2012 Jul 11
JAMA, 2008-03-05
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-08-01
International journal of radiation oncology, biology, physics, 2011-09-01
American journal of clinical oncology, 2011-02
International journal of radiation oncology, biology, physics, 2013-12-01
JAMA, 2007 Jan 17
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-03-01
Hepatology (Baltimore, Md.), 2015-06
J. Hepatol., 2016-05-01
Eur. J. Cancer, 2011-09-01
Lancet Oncol., 2015-10-01
Lancet Oncol., 2017 Oct 26
Cancer medicine, 2022 Aug 09
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-11-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-08-20
Lancet Oncol., 2019 Mar 25
N. Engl. J. Med.,
Lancet,
NEJM Evidence, 2022 Jun 1
Practical radiation oncology, 2015
Radiother Oncol, 2014 Jun
J Clin Oncol, 2013 May 1
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-02-10
Practical radiation oncology, 2015
Journal of the National Cancer Institute, 2017-09-01
N. Engl. J. Med.,
JAMA Oncol, 2021 Jan 21
Oncol Lett, 2019 Sep 10
BMC Palliat Care, 2015 Aug 04
Lancet, 2017-03-11
JAMA, 2013 Oct 9
Lancet (London, England), 2018-03-24
J. Clin. Oncol., 2020 Feb 27
Annals of surgery, 2019-04-05
N. Engl. J. Med.,
Sci Rep, 2018 Jun 06
J. Hepatol., 2017 Jan 23
The Journal of pathology, 2019-06
N. Engl. J. Med., 2019 Jun 02
Cancer,
J. Clin. Oncol., 2013 Aug 26
Cancer, 2011-09-01
International journal of radiation oncology, biology, physics, 2015-07-01
Cancer treatment reviews, 2017-02
Strahlenther Onkol, 2019 Feb 08
Radiother Oncol, 2018 Jul 09
Oncologist, 2019 Aug 07
Journal of immunotherapy (Hagerstown, Md. : 1997), 2013-09
J Immunother, 2010 Oct
J. Natl. Cancer Inst., 2017 Jan 28
JAMA Oncol,
JAMA Oncol, 2019 Oct 03
J. Hepatol., 2019 Apr 06
Ann. Surg.,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-04-01
J Hepatol, 2021 Nov 19
N Engl J Med, 2020 May 14
J Hepatol, 2021 Dec 11
Gastroenterology, 2018 May 17
Clin. Gastroenterol. Hepatol., 2018 Nov 28
Hepatology (Baltimore, Md.), 2019-10
JAMA oncology, 2019-06-01
Lancet Gastroenterol Hepatol, 2017 Jun 23
Clin. Cancer Res., 2015 Oct 23
Invest New Drugs, 2015 Apr 12
J Hepatol, 2021 May 26
NEJM Evidence, 2022 June 6
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-04-10
Cancer, 2019-09-15
Int J Cancer, 2018 Apr 15
JAMA Oncol, 2019 Oct 31
Eur J Surg Oncol, 2014 Oct 07
Sci Rep, 2016 May 20
JAMA Netw Open, 2020 Feb 05
Clinical cancer research : an official journal of the American Association for Cancer Research, 2007-06-15
Seminars in oncology, 2003-08
Annals of oncology : official journal of the European Society for Medical Oncology, 2003-07
Crit Rev Oncol Hematol, 2017 Mar 29
J. Clin. Oncol., 2020 Jan 24
Lancet Oncol., 2020 Mar 02
Lancet (London, England), 2017-06-24
The Lancet. Oncology, 2018-07
J. Clin. Oncol., 2019 Dec 02
JAMA Oncol, 2020 Dec 10
International journal of radiation oncology, biology, physics, 2016-03-15
Cancer medicine, 2019-05
American journal of clinical oncology, 2019-03
Proceedings of the National Academy of Sciences of the United States of America, 2015-11-03
Oncologist, 2020 Mar 10
Semin Diagn Pathol, 2016 Dec 23
British journal of cancer, 2005-03-14
Case Rep Oncol, 2020 Jan 21
J. Clin. Oncol., 2018 Dec 04
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2011-08
Am. J. Surg., 2013 Jul 01
J Surg Oncol, 2015 Oct 13
Nature, 2013 Aug 14
Lancet Oncol, 2020 Mar 20
Liver Cancer, 2019 Sep 18
Eur J Intern Med, 2008 Jun 10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000-07
Gastroenterology clinics of North America, 2018-06
Eur J Cancer, 2015 Jun 08
Oncotarget,
Blood, 2020 Sep 10
Blood Adv,
The New England journal of medicine, 2018-07-05
J Gastroenterol, 2019 Nov 12
Am Heart J, 2010 Sep 18
N Engl J Med,
Lancet (London, England), 2017-01-07
The Lancet. Oncology, 2019-02
Hepatology, 2019 Oct 14
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-01-20
British journal of cancer, 2016-03-29
Pancreatology, 2020 Oct 18
Lancet (London, England), 2016-02-06
European journal of cancer (Oxford, England : 1990), 2019-02
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-06-20
European journal of cancer (Oxford, England : 1990), 2018-01
Lancet,
JAMA oncology, 2018-12-01
Cancer discovery, 2017-03
Hepatology (Baltimore, Md.), 2018-08
Radiology, 2018-06
Hepatology, 2021 Mar 19
Human pathology, 2016-03
Journal of gastrointestinal cancer, 2015-06
Cancers (Basel), 2019 Jul 31
The Lancet. Oncology, 2013-04
Ann Surg,
Int J Radiat Oncol Biol Phys, 2021 Aug 01
J Clin Oncol, 2022 Jan 27
Transpl Int, 2010 May 20
Eur J Surg Oncol,
World J Surg, 2019 Apr
J Surg Oncol, 2020 Sep 24
World J Gastrointest Surg, 2019 Jun 27
Annals of oncology : official journal of the European Society for Medical Oncology, 2024 Feb 19
The New England journal of medicine, 2013-10-31
ESMO Open, 2021 Nov 24
Clin Cancer Res, 2017 Dec 29
J Clin Oncol, 2022 Mar 22
J Clin Oncol, 2021 Dec 20
J Natl Compr Canc Netw,
J Immunother Cancer, 2021 Jun
Ann Oncol, 2022 Oct 18
Cancer, 2019-01-01
HPB : the official journal of the International Hepato Pancreato Biliary Association, 2017-07
JAMA Oncol, 2021 Dec 01
Lancet, 2021 Jun 05
Eur J Cancer, 2018 Aug 24
Journal of the National Cancer Institute, 2016-06
Pediatrics, 2014 Feb 02
N. Engl. J. Med.,
The Journal of urology, 2018-12
Lancet Oncol., 2014 Feb 18
Br J Cancer, 2014 Apr 15
Cancer, 2011-06-15
Eur J Cancer, 2017 Nov 28
N. Engl. J. Med., 2019 Sep 28
Lancet Oncol, 2021 Jan 18
J Clin Oncol, 2021 Apr 19
J Clin Oncol, 2003 Jul 01
N Engl J Med, 2023 Jun 04
Lancet Oncol, 2021 May 04
Lancet Oncol, 2023 Jun 02
Cancer, 2005-01-01
Cancer chemotherapy and pharmacology, 2011-12
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010 Sep 20
British journal of cancer, 2008 Sep 16
Cancer chemotherapy and pharmacology, 2009 Jan 14
Cancer, 2007 Sep 15
Annals of oncology : official journal of the European Society for Medical Oncology, 2013 Aug 23
NEJM evidence, 2022 Jun 06
Int J Radiat Oncol Biol Phys, 2019 Oct 1
Frontiers in oncology, 2020 Mar 24
International journal of radiation oncology, biology, physics, 2023 Apr 08
Cancer, 2023 Jul 28
Gastrointestinal endoscopy, 2012-01
Gastrointestinal endoscopy, 2012 Feb
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-03-10
N Engl J Med,
Nat Med, 2020 Apr 06
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Jan 09
JAMA oncology, 2021 Jun 01
Journal of gastrointestinal oncology, 2020 Aug
American journal of clinical oncology, 2023 Dec 22
The oncologist, 2015 Jan 07
PloS one, 2023 Aug 10
Cancer, 2023 Jul 06
The Lancet. Oncology, 2023 Dec 08
Cardiovascular and interventional radiology, 2023 Jul 10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-01-20
Pract Radiat Oncol, 2021 Oct 21
Lancet (London, England), 2023 Apr 16
NEJM evidence, 2022 Jun 01
American journal of clinical oncology, 2023 Apr 10